News | October 11, 2021
Sai Life Sciences presents its midterm report
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
The platform will provide a safe and nurturing space for women, and non-binary individuals
The applications navigate through more than 100 workflows across biotech, pharma, healthcare, food, forensics, industrial and applied sciences industries
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
Now all districts of the country will have commissioned PSA Oxygen plants
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
Subscribe To Our Newsletter & Stay Updated
